Long-term results of pediatric liver transplantation for autoimmune liver disease

Clin Res Hepatol Gastroenterol. 2021 May;45(3):101537. doi: 10.1016/j.clinre.2020.08.013. Epub 2020 Oct 17.

Abstract

Background: Autoimmune hepatitis (AIH) and primary sclerosing cholangitis (PSC) are rare indications for liver transplantation (LT) in children. The aim of the present retrospective multicenter study was to evaluate long-term outcome after LT for autoimmune liver disease in childhood.

Methods: Retrospective data from 30 children who underwent a first LT from 1988 to 2018 were collected.

Results: The study population consisted of 18 girls and 12 boys, transplanted for AIH type 1 (n=14), AIH type 2 (n=7) or PSC (n=9). Mean age at LT was 11.8±5.2 years. The main indications for LT were acute (36.7%) or chronic end-stage liver failure (63.3%). Graft rejection occurred in 19 patients (63.3%); 6 pts required retransplantation for chronic rejection. Recurrence of initial disease was observed in 6 patients (20.0%), all of them with type 1 AIH, after a median time of 42 months, requiring retransplantation in 2 cases. Overall patient survival rates were 96.4%, 84.6%, 74.8%, 68.0%, 68.0%, 68.0% and 68.0% at 1, 5, 10, 15, 20, 25 and 30 years, respectively. Age at LT<1year (p<0.0001), LT for fulminant failure (p=0.023) and LT for type 2 AIH (p=0.049) were significant predictive factors of death.

Conclusion: Long-term outcome after LT for pediatric autoimmune liver disease is impaired in patients with AIH because of consistent complications such as rejection and disease recurrence.

Keywords: Auto-immune disease; Liver transplantation; Outcome; Pediatric; Survival.

Publication types

  • Multicenter Study

MeSH terms

  • Child
  • Cholangitis, Sclerosing*
  • End Stage Liver Disease*
  • Female
  • Hepatitis, Autoimmune* / surgery
  • Humans
  • Liver Transplantation*
  • Male
  • Retrospective Studies